These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38169900)

  • 1. Development and optimisation of a reception testing protocol designed to eliminate HCV in the UK prison population.
    Mongale E; Allen S; Brew I; Ludlow-Rhodes A; Royal N; Waldron J; Alexander H; Christensen L; Dorrington K; Milner A; Missen L; Jones A; Troke PJF
    JHEP Rep; 2024 Jan; 6(1):100937. PubMed ID: 38169900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis C elimination prison initiative: HCV-intensive test and treat, a whole prisoner population HCV test-and-treat program in England.
    Halford R; Christensen L; Cox S; Sheehan J; Brew I; Gillyon-Powell M; Threadgold G; O'Moore É; Troke PJF; Jones A
    Health Sci Rep; 2023 Dec; 6(12):e1724. PubMed ID: 38125280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
    J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    Morey S; Hamoodi A; Jones D; Young T; Thompson C; Dhuny J; Buchanan E; Miller C; Hewett M; Valappil M; Hunter E; McPherson S
    J Viral Hepat; 2019 Jan; 26(1):101-108. PubMed ID: 30315691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
    Connoley D; Francis-Graham S; Storer M; Ekeke N; Smith C; Macdonald D; Rosenberg W
    J Viral Hepat; 2020 Oct; 27(10):987-995. PubMed ID: 32449969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testing.
    Perrett SE; Plimmer A; Shankar AG; Craine N
    J Public Health (Oxf); 2020 May; 42(2):423-428. PubMed ID: 32090269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV micro-elimination in two prisons in Milan, Italy: A model of care.
    Giuliani R; Casigliani V; Fornili M; Sebastiani T; Freo E; Arzilli G; Scardina G; Baglietto L; Tavoschi L; Ranieri R
    J Viral Hepat; 2020 Dec; 27(12):1444-1454. PubMed ID: 32815623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons.
    Sheehan Y; Cochrane A; Treloar C; Grebely J; Tedla N; Lloyd AR; Lafferty L
    Int J Drug Policy; 2024 Aug; 130():104516. PubMed ID: 38996643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for hepatitis C virus infection in UK prisons: What actually happens?
    Jack K; Thomson BJ; Irving WL
    J Viral Hepat; 2019 Jun; 26(6):644-654. PubMed ID: 30702194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C.
    Fiore V; De Matteis G; Ranieri R; Saderi L; Pontali E; Muredda A; Ialungo AM; Caruso R; Madeddu G; Sotgiu G; Babudieri S
    Int J Drug Policy; 2021 Apr; 90():103055. PubMed ID: 33310637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
    Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
    Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.
    Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR
    Int J Drug Policy; 2022 Jan; 99():103456. PubMed ID: 34560624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England.
    Mohamed Z; Al-Kurdi D; Nelson M; Shimakawa Y; Selvapatt N; Lacey J; Thursz MR; Lemoine M; Brown AS
    Int J Drug Policy; 2020 Jan; 75():102608. PubMed ID: 31759307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons.
    Bhandari R; Morey S; Hamoodi A; Thompson C; Jones D; Hewett M; Hunter E; Taha Y; McPherson S
    J Viral Hepat; 2020 Apr; 27(4):449-452. PubMed ID: 31749225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.